(RTTNews) - Merck & Co Inc. (MRK) on Wednesday said Health Canada has approved Keytruda for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC).
The approval is based on positive results from the Phase 3 KEYNOTE-689 study, in which perioperative Keytruda in combination with adjuvant radiotherapy reduced the risk of event free survival (EFS) by 30%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Health Canada Approves Merck's Keytruda For Patients With Resectable Locally Advanced HNSCC
Published 2 months ago
Aug 13, 2025 at 11:34 AM
Neutral
Auto